Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aclidinium bromide: Phase IIa data

In a double-blind Phase IIa trial in 17 patients, single doses of 100, 300

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE